MedicarePartD.guide

A non-government resource built from CMS public data

Hepatitis C drugs on HealthSpring Assurance Rx (S5617-222)

Epclusa, Mavyret, Harvoni and their generics, checked against this plan's 2026 formulary (its list of covered drugs).

Plan type
Stand-alone drug plan (PDP), Indiana + 1 more
Premium
$117.80/month
Deductible
$615.00
Change plan

3 of 6 Hepatitis C drugs are covered on this plan. All 3 require prior authorization.

3 aren't on the formulary, including sofosbuvir-velpatasvir and Mavyret.

  • Epclusa
    sofosbuvir and velpatasvir
    Covered · prior auth
    from $6,018.66
    Tier 5
  • Harvoni
    ledipasvir and sofosbuvir
    Covered · prior auth
    from $7,462.20
    Tier 5
  • Vosevi
    sofosbuvir
    Covered · prior auth
    $5,938.00
    Tier 5
Not on the formulary
sofosbuvir-velpatasvir, Mavyret, ledipasvir-sofosbuvir

Patient cost for a 30-day supply at a preferred retail pharmacy, after the $615.00 deductible where it applies. Where the plan charges a percentage (coinsurance), the dollar figure is that share of the plan's negotiated price; "from" means other strengths cost more. Data from the CMS 2026 Part D formulary and pricing files.

Full plan details · This plan's whole drug list